Title

Peritoneal Nebulization of Ropivacaine for Pain Control After Laparoscopic Colectomy
A Multicentric, Randomized, Controlled, Double Blinded, Phase III Clinical Trial; Comparing Peritoneal Nebulization of Ropivacaine 150 mg With Peritoneal Nebulization of Saline
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Status

    Terminated
  • Study Participants

    130
The purpose of this study is to assess if intraperitoneal nebulization of Ropivacaine 150 mg produces better postoperative pain control than Saline nebulization after laparoscopic colectomy.
Recently intraperitoneal nebulization of local anesthetic has been used as an alternative to direct intraperitoneal instillation. Intraperitoneal aerosolization of Bupivacaine 50 mg after laparoscopic cholecystectomy significantly reduced postoperative pain, morphine consumption and incidence of postoperative nausea and vomiting and it is associated with rapid mobilization compared with patients receiving direct instillation of Bupivacaine 50 mg or placebo.

In a recent study the investigators found that nebulization of Ropivacaine 30 mg with the AeronebPro® before or after laparoscopic cholecystectomy and gynecologic laparoscopic surgery reduces postoperative pain and morphine consumption. Patients receiving preoperative nebulization of Ropivacaine presented significantly less postoperative pain (-50% clinical setting) and consumed significant less morphine (-50% and -40% respectively) than patients in control groups during the first 48 hours after surgery.

The effects of peritoneal nebulization of ropivacaine during laparoscopic colectomy on pain control and morphine consumption were not evaluated.

The investigators hypothesize that intraperitoneal nebulization of Ropivacaine may produce better pain control and less morphine consumption than nebulization of saline after laparoscopic colectomy.
Study Started
Sep 30
2011
Primary Completion
Dec 31
2012
Study Completion
Dec 31
2012
Last Update
Feb 25
2013
Estimate

Drug Ropivacaine 150 mg

Nebulization of Ropivacaine 150 mg in the peritoneal cavity

  • Other names: Nebulization Ropivacaine

Drug saline 15 ml

Nebulization of saline 15 ml in the peritoneal cavity

  • Other names: Nebulization Saline

Ropivacaine 150 mg Experimental

Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system

Saline 15 ml Placebo Comparator

Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system

Criteria

Inclusion Criteria:

Females and Males 18-80 years old
ASA Score I (American Society of Anesthesiologists classification : a normal healthy patient.
ASA Score II (American Society of Anesthesiologists classification): A patient with mild systemic disease
ASA Score III (American Society of Anesthesiologists classification): A patient with severe systemic disease
Patients scheduled for oncological laparoscopic colectomy
Patients who do not use opioids analgesic drugs before surgery
Patients without cognitive impairment or mental retardation

Exclusion Criteria:

Females and Males under 18 or over 80
ASA Score IV (American Society of Anesthesiologists classification): A patient with severe systemic disease that is a constant threat to life
ASA Score V (American Society of Anesthesiologists classification): A moribund patient who is not expected to survive without the operation
Emergency/urgency surgery
Postoperative admission in an intensive care unit with sedation or ventilatory assistance
Cognitive impairment or mental retardation
Use of opiods before surgery
Progressive degenerative diseases of the CNS
Convulsions or chronic therapy with antiepileptic drugs
Severe hepatic or renal impairment
Allergy to one of the specific drugs under study
Acute infection or inflammatory chronic disease
Alcohol or drug addiction
Any kind of communication problem
Neurologic or psychiatric disease
No Results Posted